Importance of venture capital investors for the industrial biotechnology industry

Authors

  • Gunter Festel FESTEL CAPITAL
  • Christian Rammer

DOI:

https://doi.org/10.5912/jcb685

Keywords:

Industrial biotechnology, bioeconomy, new ventures, venture capital

Abstract

As in the medical biotechnology area some decades ago, the fast technological development within industrial biotechnology (IB) has caused numerous new ventures. Venture capital (VC) has become a major capital source for these companies and VC investors have particularly allocated financing to research and development (R&D) based companies. Since the early 2000s, the global net stock of VC investments in IB companies has continuously increased over the past 12 years and exceeded 3.5 billion US dollars at the end of 2013. In 2013, the gross amount of VC money was 386 million US dollars distributed to 20 companies corresponding to an average amount of 19.3 million US dollars for each company. The rising capital contribution into the IB sector indicates that it is seen as an attractive investment opportunity for VC investors. Analysing the VC investments by segments shows that there is a strong preference for biofuels and biochemicals. The regional breakdown of VC activities shows that the Americas are the leading region followed by Europe.

References

Coons, R. (2010) Industrial Biotechnology. Chemical Week 172: 22-26.

Festel, G. (2010) Industrial biotechnology: Market size, company types, business models, and growth strategies. Industrial Biotechnology 6: 88-94.

EuropaBio (2003) White Biotechnology: Gateway to a More Sustainable Future. Brussels: EuropaBio.

SusChem (2005) Industrial or White Biotechnology. Brussels: EuropaBio.

Festel, G., Detzel, C. and Maas, R. (2012) Industrial biotechnology – Markets and industry structure. Journal of Commercial Biotechnology 18(1): 11-21.

Hermann, B.G., Blok, K. and Patel, M.K. (2007) Producing Bio-Based Bulk Chemicals Using Industrial Biotechnology Saves Energy and Combats Climate Change. Environmental Science & Technology 41: 7915-7921.

Festel, G., Knöll, J. and Götz, H. (2004) Industrial Biotech - Influencing Produc-tion. Chemistry & Industry 7: 21-22.

Festel, G. (2011) Drivers and barriers for industrial biotechnology. International Sugar Journal 113(1345): 19-23.

Yang, W. (2014) 2013 - Biotech back in the saddle. Nature Biotech 32: 126-126.

Huggett, B. (2014) Biotech's wellspring: the health of private biotech in 2013. Nature Biotech 32: 428-435.

Published

2015-04-01

Issue

Section

Articles